Anti-CTLA-4 therapy for malignant mesothelioma

Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1. This special report aims to describe the state of clin...

Full description

Saved in:
Bibliographic Details
Published inImmunotherapy Vol. 9; no. 3; pp. 273 - 280
Main Authors Guazzelli, Alice, Bakker, Emyr, Krstic-Demonacos, Marija, Lisanti, Michael P, Sotgia, Federica, Mutti, Luciano
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.03.2017
Subjects
Animals
anti-CLTA-4
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents - therapeutic use
B7-H1 Antigen - immunology
B7-H1 Antigen - metabolism
Biomarkers
Cancer therapies
Chemotherapy
Clinical trials
Clinical Trials as Topic
CTLA-4 Antigen - immunology
CTLA-4 Antigen - metabolism
CTLA-4 protein
Humans
Immune checkpoint inhibitors
Immune system
Immunoglobulins
Immunotherapy
Immunotherapy - methods
Ligands
Lung Neoplasms - immunology
Lung Neoplasms - therapy
Lymphocyte Activation
Lymphocytes
malignant mesothelioma
Medical prognosis
Melanoma
Mesothelioma
Mesothelioma - immunology
Mesothelioma - therapy
Mesothelioma, Malignant
Metastases
Neoplasm Metastasis
PD-1 protein
PD-L1 protein
Programmed Cell Death 1 Receptor - immunology
Programmed Cell Death 1 Receptor - metabolism
Solid tumors
Studies
T-Lymphocytes - immunology
Treatment Outcome
Tumors
United States > US
Chicago Illinois
malignant mesothelioma
immunotherapy
anti-CLTA-4
Online AccessGet full text

Cover

Abstract Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1. This special report aims to describe the state of clinical trials of tremelimumab in patients with unresectable malignant mesothelioma (MM) in particular with regard to the clinical efficacy, safety and tolerability. Criticism and perspective of this treatment are also discussed. Biological and clinical considerations rule out the use of tremelimumab as single agent for MM and, more generally, the use of immune checkpoint inhibitors for MM is still largely questionable and not supported by evidences.
AbstractList Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1. This special report aims to describe the state of clinical trials of tremelimumab in patients with unresectable malignant mesothelioma (MM) in particular with regard to the clinical efficacy, safety and tolerability. Criticism and perspective of this treatment are also discussed. Biological and clinical considerations rule out the use of tremelimumab as single agent for MM and, more generally, the use of immune checkpoint inhibitors for MM is still largely questionable and not supported by evidences.
Author Lisanti, Michael P
Mutti, Luciano
Krstic-Demonacos, Marija
Guazzelli, Alice
Bakker, Emyr
Sotgia, Federica
AuthorAffiliation 1Biomedical Research Centre, School of Environment & Life Sciences, University of Salford, Salford, UK
AuthorAffiliation_xml – name: 1Biomedical Research Centre, School of Environment & Life Sciences, University of Salford, Salford, UK
Author_xml – sequence: 1
  givenname: Alice
  surname: Guazzelli
  fullname: Guazzelli, Alice
– sequence: 2
  givenname: Emyr
  surname: Bakker
  fullname: Bakker, Emyr
– sequence: 3
  givenname: Marija
  surname: Krstic-Demonacos
  fullname: Krstic-Demonacos, Marija
– sequence: 4
  givenname: Michael P
  surname: Lisanti
  fullname: Lisanti, Michael P
– sequence: 5
  givenname: Federica
  surname: Sotgia
  fullname: Sotgia, Federica
– sequence: 6
  givenname: Luciano
  surname: Mutti
  fullname: Mutti, Luciano
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28231719$$D View this record in MEDLINE/PubMed
BookMark eNp1kLtPwzAQhy1URB8wsqJILCwufsV2xqriJVViKRKb5TgOuEqcYidD_3tcpTAgMfms--6nu28OJr7zFoBrjJaEYHHv2h4ShDlEmNAzMMMiR1AwJie_NX2fgnmMO4Q4E5xdgCmRhGKBixlYrnzv4Hq7WUGW9Z826P0hq7uQtbpxH177Pmtt7FKncV2rL8F5rZtor07vArw9PmzXz3Dz-vSyXm2gyVHRQ15gyyQ2XJTGGFSUJWO4YtrKgiIqK1RTzXOJq4oTxvKcUElqjbguRcUtonQB7sbcfei-Bht71bpobNNob7shKiyFkDidJhJ6-wfddUPwaTtFKKGMcsFJouBImdDFGGyt9sG1OhwURuooUiWR6ihSHUUm_uaUOpStrX7pH3MJKEagHvoh2Gic9caq8ZcmnHHe_hP-DdPtgLs
CitedBy_id crossref_primary_10_12688_f1000research_15796_1
crossref_primary_10_3390_cancers12020366
crossref_primary_10_1038_nrc_2017_42
crossref_primary_10_1016_j_lfs_2022_120716
crossref_primary_10_1016_j_omto_2020_01_009
crossref_primary_10_1080_21678707_2017_1325358
crossref_primary_10_5606_fng_btd_2021_25066
crossref_primary_10_1016_j_freeradbiomed_2018_10_401
crossref_primary_10_1080_14737140_2017_1358091
crossref_primary_10_1080_13543784_2017_1351545
crossref_primary_10_3390_cancers11030305
crossref_primary_10_3390_cancers14246063
crossref_primary_10_1080_14712598_2017_1378640
Cites_doi 10.1111/cts.12391
10.1016/S2213-2600(15)00092-2
10.1016/j.febslet.2013.10.015
10.1073/pnas.1320318110
10.1056/NEJMra050152
10.1084/jem.173.3.721
10.1016/j.jtho.2016.07.033
10.2307/3433543
10.1097/JTO.0000000000000177
10.1056/NEJMc1213514
10.1016/1074-7613(95)90125-6
10.1158/1078-0432.CCR-15-1130
10.1158/1538-7445.AM2015-CT103
10.1016/j.bbamcr.2015.08.003
10.1172/JCI83871
10.1200/JCO.2003.11.136
10.4049/jimmunol.0901060
10.1007/s10147-016-0959-z
10.1038/ng.912
10.1093/annonc/mds256
10.1016/j.bbacli.2015.04.001
10.1177/107327480601300402
10.1046/j.1440-1711.1999.00795.x
10.1056/NEJMoa1003466
10.1158/1078-0432.CCR-07-0629
10.1200/JCO.2016.34.15_suppl.8502
10.1177/172460081002500307
10.1097/CJI.0b013e31823aa41c
10.1002/(SICI)1097-0215(19981209)78:6<740::AID-IJC12>3.0.CO;2-5
10.1016/S0169-5002(00)00192-6
10.1186/1479-5876-9-196
10.1111/j.1365-2249.2004.02478.x
10.1016/j.jtcvs.2007.10.026
10.1016/j.humpath.2016.01.010
10.1200/JCO.2016.34.15_suppl.TPS8575
10.1158/1078-0432.CCR-09-1624
10.1183/09031936.06.00135305
10.1056/NEJMoa1302369
10.1111/j.1600-065X.2009.00771.x
10.1158/1535-7163.MCT-11-1014
10.1158/1078-0432.CCR-10-2232
10.1097/COC.0000000000000239
10.1158/1078-0432.CCR-10-0505
10.1126/science.270.5238.985
10.3322/caac.20132
10.1038/sj.bjc.6600174
10.1016/j.lungcan.2006.01.007
10.3389/fimmu.2015.00421
10.1002/jcp.22600
10.2217/imt.13.9
10.1200/JCO.2014.59.4358
10.1016/S1470-2045(13)70381-4
10.1016/S0140-6736(05)67025-0
10.1053/sonc.2002.30227
10.1373/clinchem.2012.185363
10.1093/intimm/dxu076
10.1080/2162402X.2016.1190061
10.1056/NEJMoa1504030
10.1038/nri2326
10.1093/carcin/bgt166
ContentType Journal Article
Copyright Future Medicine Ltd
Copyright Future Medicine Ltd Mar 2017
Copyright_xml – notice: Future Medicine Ltd
– notice: Copyright Future Medicine Ltd Mar 2017
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7T5
7X7
7XB
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
EHMNL
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
PQEST
PQQKQ
PQUKI
PRINS
DOI 10.2217/imt-2016-0123
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
UK & Ireland Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Health & Medical Collection (Alumni Edition)
Medical Database
Biological Science Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
UK & Ireland Database
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest Central (Alumni)
DatabaseTitleList AIDS and Cancer Research Abstracts
MEDLINE
ProQuest Central Student
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1750-7448
EndPage 280
ExternalDocumentID 10_2217_imt_2016_0123
28231719
Genre Journal Article
Review
GeographicLocations United States--US
Chicago Illinois
GeographicLocations_xml – name: United States--US
– name: Chicago Illinois
GroupedDBID -
0R
3V.
53G
70G
7X7
88E
8AO
8C1
8FE
8FH
8FI
8FJ
ABUWG
ACGFS
ACPRK
AENEX
AFKRA
AHMBA
ALMA_UNASSIGNED_HOLDINGS
BBAFP
BBNVY
BENPR
BHPHI
BPHCQ
BVXVI
EBS
EHMNL
EJD
F5P
FYUFA
H13
HCIFZ
HZ
IAO
IEA
IHR
LK8
M1P
M7P
MV1
NTCAX
O9-
PQQKQ
PRINS
PSQYO
RFM
ABJNI
CGR
CUY
CVF
ECM
EIF
NPM
---
0R~
4.4
AAYXX
ACWKX
ADBBV
AFFYO
ALIPV
CCPQU
CITATION
HMCUK
HZ~
ITC
M4Z
OVD
PROAC
RPM
TDBHL
TEORI
TFL
TFMDE
TMEDX
UKHRP
7T5
7XB
8FK
AZQEC
DWQXO
GNUQQ
H94
K9.
PQEST
PQUKI
ID FETCH-LOGICAL-c509t-691e481c67bccc09bb441d4ae893038d0f3a6581dd6244552382fa06ab7d6e033
IEDL.DBID 8C1
ISSN 1750-743X
IngestDate Thu Aug 15 22:35:21 EDT 2024
Fri Sep 13 00:20:28 EDT 2024
Thu Sep 12 19:26:27 EDT 2024
Fri Feb 23 03:35:44 EST 2024
Tue Jan 05 21:42:19 EST 2021
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords malignant mesothelioma
immunotherapy
anti-CLTA-4
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c509t-691e481c67bccc09bb441d4ae893038d0f3a6581dd6244552382fa06ab7d6e033
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://clok.uclan.ac.uk/21179/1/Accepted%20Manuscript%20Anti-CTLA4.pdf
PMID 28231719
PQID 2323436762
PQPubID 55027
PageCount 8
ParticipantIDs proquest_miscellaneous_1877817437
proquest_journals_2323436762
crossref_primary_10_2217_imt_2016_0123
pubmed_primary_28231719
futurescience_futuremedicine_10_2217_imt_2016_0123
ProviderPackageCode RFM
NTCAX
70G
PublicationCentury 2000
PublicationDate 2017-03-01
PublicationDateYYYYMMDD 2017-03-01
PublicationDate_xml – month: 03
  year: 2017
  text: 2017-03-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Immunotherapy
PublicationTitleAlternate Immunotherapy
PublicationYear 2017
Publisher Future Medicine Ltd
Publisher_xml – name: Future Medicine Ltd
References e_1_3_2_28_1
Valle MT (e_1_3_2_48_1) 2003; 11
e_1_3_2_49_1
e_1_3_2_20_1
e_1_3_2_41_1
e_1_3_2_66_1
e_1_3_2_22_1
e_1_3_2_43_1
e_1_3_2_64_1
e_1_3_2_24_1
e_1_3_2_45_1
e_1_3_2_26_1
e_1_3_2_47_1
e_1_3_2_62_1
e_1_3_2_60_1
e_1_3_2_16_1
e_1_3_2_39_1
e_1_3_2_9_1
e_1_3_2_18_1
e_1_3_2_7_1
e_1_3_2_31_1
e_1_3_2_10_1
e_1_3_2_33_1
e_1_3_2_12_1
e_1_3_2_35_1
e_1_3_2_58_1
e_1_3_2_14_1
e_1_3_2_37_1
e_1_3_2_56_1
e_1_3_2_3_1
e_1_3_2_50_1
Neumann V (e_1_3_2_5_1) 2013; 110
e_1_3_2_27_1
e_1_3_2_29_1
e_1_3_2_42_1
e_1_3_2_65_1
e_1_3_2_21_1
e_1_3_2_44_1
e_1_3_2_63_1
e_1_3_2_23_1
e_1_3_2_46_1
e_1_3_2_25_1
e_1_3_2_61_1
e_1_3_2_40_1
Nishino M (e_1_3_2_54_1) 2016; 4
e_1_3_2_17_1
e_1_3_2_38_1
e_1_3_2_8_1
e_1_3_2_19_1
e_1_3_2_2_1
Nishino M GM (e_1_3_2_52_1) 2014; 2
e_1_3_2_30_1
e_1_3_2_55_1
e_1_3_2_11_1
e_1_3_2_32_1
e_1_3_2_53_1
e_1_3_2_6_1
e_1_3_2_13_1
e_1_3_2_34_1
e_1_3_2_59_1
e_1_3_2_4_1
e_1_3_2_15_1
e_1_3_2_36_1
e_1_3_2_57_1
e_1_3_2_51_1
References_xml – ident: e_1_3_2_64_1
  doi: 10.1111/cts.12391
– ident: e_1_3_2_57_1
  doi: 10.1016/S2213-2600(15)00092-2
– ident: e_1_3_2_14_1
  doi: 10.1016/j.febslet.2013.10.015
– ident: e_1_3_2_66_1
  doi: 10.1073/pnas.1320318110
– ident: e_1_3_2_4_1
  doi: 10.1056/NEJMra050152
– ident: e_1_3_2_25_1
  doi: 10.1084/jem.173.3.721
– ident: e_1_3_2_36_1
  doi: 10.1016/j.jtho.2016.07.033
– ident: e_1_3_2_42_1
  doi: 10.2307/3433543
– ident: e_1_3_2_34_1
  doi: 10.1097/JTO.0000000000000177
– ident: e_1_3_2_10_1
  doi: 10.1056/NEJMc1213514
– ident: e_1_3_2_30_1
  doi: 10.1016/1074-7613(95)90125-6
– ident: e_1_3_2_9_1
  doi: 10.1158/1078-0432.CCR-15-1130
– volume: 4
  issue: 30
  year: 2016
  ident: e_1_3_2_54_1
  article-title: Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a ‘common language’ for the new arena of cancer treatment
  publication-title: J. Immunother. Cancer
  contributor:
    fullname: Nishino M
– ident: e_1_3_2_61_1
  doi: 10.1158/1538-7445.AM2015-CT103
– ident: e_1_3_2_24_1
  doi: 10.1016/j.bbamcr.2015.08.003
– volume: 2
  issue: 17
  year: 2014
  ident: e_1_3_2_52_1
  article-title: Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?
  publication-title: J. Immunother. Cancer
  contributor:
    fullname: Nishino M GM
– ident: e_1_3_2_58_1
– ident: e_1_3_2_15_1
  doi: 10.1172/JCI83871
– ident: e_1_3_2_13_1
  doi: 10.1200/JCO.2003.11.136
– ident: e_1_3_2_33_1
  doi: 10.4049/jimmunol.0901060
– ident: e_1_3_2_22_1
  doi: 10.1007/s10147-016-0959-z
– ident: e_1_3_2_7_1
  doi: 10.1038/ng.912
– ident: e_1_3_2_38_1
  doi: 10.1093/annonc/mds256
– ident: e_1_3_2_17_1
  doi: 10.1016/j.bbacli.2015.04.001
– ident: e_1_3_2_3_1
  doi: 10.1177/107327480601300402
– ident: e_1_3_2_23_1
  doi: 10.1046/j.1440-1711.1999.00795.x
– ident: e_1_3_2_21_1
  doi: 10.1056/NEJMoa1003466
– ident: e_1_3_2_12_1
  doi: 10.1158/1078-0432.CCR-07-0629
– ident: e_1_3_2_59_1
  doi: 10.1200/JCO.2016.34.15_suppl.8502
– volume: 110
  start-page: 319
  issue: 18
  year: 2013
  ident: e_1_3_2_5_1
  article-title: Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health
  publication-title: Dtsch. Arztebl. Int.
  contributor:
    fullname: Neumann V
– ident: e_1_3_2_11_1
  doi: 10.1177/172460081002500307
– ident: e_1_3_2_55_1
  doi: 10.1097/CJI.0b013e31823aa41c
– ident: e_1_3_2_45_1
  doi: 10.1002/(SICI)1097-0215(19981209)78:6<740::AID-IJC12>3.0.CO;2-5
– volume: 11
  start-page: 161
  issue: 2
  year: 2003
  ident: e_1_3_2_48_1
  article-title: Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone
  publication-title: Int. J. Mol. Med.
  contributor:
    fullname: Valle MT
– ident: e_1_3_2_47_1
  doi: 10.1016/S0169-5002(00)00192-6
– ident: e_1_3_2_20_1
  doi: 10.1186/1479-5876-9-196
– ident: e_1_3_2_26_1
  doi: 10.1111/j.1365-2249.2004.02478.x
– ident: e_1_3_2_43_1
  doi: 10.1016/j.jtcvs.2007.10.026
– ident: e_1_3_2_35_1
  doi: 10.1016/j.humpath.2016.01.010
– ident: e_1_3_2_65_1
  doi: 10.1200/JCO.2016.34.15_suppl.TPS8575
– ident: e_1_3_2_53_1
  doi: 10.1158/1078-0432.CCR-09-1624
– ident: e_1_3_2_44_1
  doi: 10.1183/09031936.06.00135305
– ident: e_1_3_2_62_1
  doi: 10.1056/NEJMoa1302369
– ident: e_1_3_2_27_1
  doi: 10.1111/j.1600-065X.2009.00771.x
– ident: e_1_3_2_31_1
  doi: 10.1158/1535-7163.MCT-11-1014
– ident: e_1_3_2_40_1
  doi: 10.1158/1078-0432.CCR-10-2232
– ident: e_1_3_2_60_1
  doi: 10.1097/COC.0000000000000239
– ident: e_1_3_2_56_1
  doi: 10.1158/1078-0432.CCR-10-0505
– ident: e_1_3_2_29_1
  doi: 10.1126/science.270.5238.985
– ident: e_1_3_2_16_1
  doi: 10.3322/caac.20132
– ident: e_1_3_2_46_1
  doi: 10.1038/sj.bjc.6600174
– ident: e_1_3_2_49_1
  doi: 10.1016/j.lungcan.2006.01.007
– ident: e_1_3_2_39_1
  doi: 10.3389/fimmu.2015.00421
– ident: e_1_3_2_50_1
  doi: 10.1002/jcp.22600
– ident: e_1_3_2_32_1
  doi: 10.2217/imt.13.9
– ident: e_1_3_2_41_1
  doi: 10.1200/JCO.2014.59.4358
– ident: e_1_3_2_51_1
  doi: 10.1016/S1470-2045(13)70381-4
– ident: e_1_3_2_2_1
  doi: 10.1016/S0140-6736(05)67025-0
– ident: e_1_3_2_6_1
  doi: 10.1053/sonc.2002.30227
– ident: e_1_3_2_37_1
  doi: 10.1373/clinchem.2012.185363
– ident: e_1_3_2_19_1
  doi: 10.1093/intimm/dxu076
– ident: e_1_3_2_18_1
  doi: 10.1080/2162402X.2016.1190061
– ident: e_1_3_2_63_1
  doi: 10.1056/NEJMoa1504030
– ident: e_1_3_2_28_1
  doi: 10.1038/nri2326
– ident: e_1_3_2_8_1
  doi: 10.1093/carcin/bgt166
SSID ssj0064764
ssib008506956
Score 2.231084
SecondaryResourceType review_article
Snippet Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to...
SourceID proquest
crossref
pubmed
futurescience
SourceType Aggregation Database
Index Database
Publisher
StartPage 273
SubjectTerms Animals
anti-CLTA-4
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents - therapeutic use
B7-H1 Antigen - immunology
B7-H1 Antigen - metabolism
Biomarkers
Cancer therapies
Chemotherapy
Clinical trials
Clinical Trials as Topic
CTLA-4 Antigen - immunology
CTLA-4 Antigen - metabolism
CTLA-4 protein
Humans
Immune checkpoint inhibitors
Immune system
Immunoglobulins
Immunotherapy
Immunotherapy - methods
Ligands
Lung Neoplasms - immunology
Lung Neoplasms - therapy
Lymphocyte Activation
Lymphocytes
malignant mesothelioma
Medical prognosis
Melanoma
Mesothelioma
Mesothelioma - immunology
Mesothelioma - therapy
Mesothelioma, Malignant
Metastases
Neoplasm Metastasis
PD-1 protein
PD-L1 protein
Programmed Cell Death 1 Receptor - immunology
Programmed Cell Death 1 Receptor - metabolism
Solid tumors
Studies
T-Lymphocytes - immunology
Treatment Outcome
Tumors
Title Anti-CTLA-4 therapy for malignant mesothelioma
URI http://dx.doi.org/10.2217/imt-2016-0123
https://www.ncbi.nlm.nih.gov/pubmed/28231719
https://www.proquest.com/docview/2323436762/abstract/
https://search.proquest.com/docview/1877817437
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Li9swEB72cSmU0nfTboMKJadVI1mKJJ9KGrKEsgmhZCE3Y8vyEmicbeM95N93xo8Ne9iejG1szHik7xtp5huAryIOo5AHw7UVgutCjHiKMM2dcSJTuihUvaY7X5jZjf65Hq1PYNbVwlBaZTcn1hN1vvO0Rj5E5Fea5MWiYZrRKoCvht_v_nDqH0X7rG0zjVM4l-ii1MTBTY6eS7psManGNHO00bYWlkLsFBwxdN2ob0bIz4ebbYWuIynOjtQjtHreyHy00PQ0Ja2h6eolvGg5JRs3TvAKTkL5GgbLRpT6cMlWxxqr_SUbsOVRrvrwBr6Ny2rDJ6vrMdesKcc6MKSybIsU_ZbyZNg27KlQ6_dmt03fws3VdDWZ8baLAvdIBipuYhm0k97YzHsv4ixDBpTrNCBTEcrlolAp0hCZ5wahfoSBqYuKVJg0s7kJQql3cFbuyvABGIZnvtAukyqk2rjYhUC7mnHupc2cVz0YdNZK7hqxjASDDDJrgmZNyKwJmbUH0SNbJs1Zl07w1EMXncGTdqDtk6Nb9ODLw20cIrTvkZZhd79PpLPWUeRle_C--VEPnxfRNqiV8cf_v_wTPIsIz-vksws4q_7eh8_IRqqsD6d2bfu1u_Xh_Md0sfyFx-lsvrjGq4vl_B93QN6u
link.rule.ids 315,786,790,12083,12250,21416,27957,27958,31754,31755,33301,33302,33779,33780,43345,43614,43840,74102,74371,74659
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3PT9swFLY2dtgkhID9oIyBkaae8LBj13ZOU1UNla0gDkXqzUocZ6pEU1jCof_93otTKg5wjKxE0fOzv-_5vfeZkO88DYNQBM2U4Zypkg9YBjDNrLY8l6osZXume3Wtx7fq92ww6w7c6q6scr0ntht1sfR4Rn4OyC8VyoslP-8fGN4ahdnV7gqNt-QdjAnUzrejjb-iGluKWjFxZ9bKtHJSgJicAXLOouZmAqz8fL5owGEERteJfIZR21HcowOkl4loC0gXu2SnY5J0GKd-j7wJ1T7p30Qp6tUZnW46q-oz2qc3G5Hq1UfyY1g1czaaToZM0diEtaJAYOkCiPlfrI6hi1Bje9bdfLnIPpHbi1_T0Zh1dycwDxSgYToVQVnhtcm99zzNc-A9hcoC8BMubcFLmQH5EEWhAeAHEI7apMy4znJT6MCl_Ey2qmUVDgiFoMyXyuZChkxpm9oQMJeZFl6Y3HrZI_21tdx9lMhwEFqgWR2Y1aFZHZq1R5JntnTxaV1E8NJLR2uDu2551W7jDD1y-jQMCwOzHVkVlo-1E9YYi_GW6ZEvcaKefi_B5KcR6eHrHz8h78fTq4mbXF7_-Uo-JIjobfnZEdlq_j2Gb8BHmvy4dbr_BfjYwA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1db9MwFL2CTUJIE-KbwgAjoT7N1Ikd23lCZawaMKoKdVLfrMRxUCWabiR76L_nOnZb7WE8RlGi6ObY51zf62OAjyx3maucpEIxRkXNMlogTVMtNSu5qGver-n-nMrzS_F9kS1i_1Mb2yq3c2I_UVdr69fIR8j8XHh7sXRUx7aI2dfJ56tr6k-Q8pXWeJzGfThUQmaI8MMvZ9PZrx26vDdb7p1jwjwtherNpZA_GUUeXQQHzhQ1-mi56hA-ic-1U36LsY6C1Uekp7tlaU9Pk8fwKOpKMg5AeAL3XPMUhrNgTL05IfP9Pqv2hAzJbG9ZvXkGn8ZNt6Sn84sxFSRsydoQlLNkhTL9t--VISvX-s1af5brVfEcLidn89NzGk9SoBYFQUdlnjihEytVaa1leVmiCqpE4VCtMK4rVvMCpUhSVRLpPsPkVKd1wWRRqko6xvkLOGjWjXsFBFM0WwtdJtwVQupcO-crm3llE1Vqywcw3EbLXAXDDIOJhg-rwbAaH1bjwzqA9FYsTbjathTc9dDxNuAmDrbW7KExgA-72zhMfO2jaNz6pjWJVkr77EsN4GX4UbvPS30pVCX56_-__D08QMSZi2_TH2_gYerpve9FO4aD7u-Ne4vipCvfRdT9A3Hc3pg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Anti-CTLA-4+therapy+for+malignant+mesothelioma&rft.jtitle=Immunotherapy&rft.au=Guazzelli%2C+Alice&rft.au=Bakker%2C+Emyr&rft.au=Krstic-Demonacos%2C+Marija&rft.au=Lisanti%2C+Michael+P&rft.date=2017-03-01&rft.issn=1750-743X&rft.volume=9&rft.issue=3&rft.spage=273&rft.epage=273&rft_id=info:doi/10.2217%2Fimt-2016-0123&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-743X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-743X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-743X&client=summon